Suppression of non-sustained ventricular tachycardia with ranolazine: A case report

Wisconsin Medical Journal

Volumn 108, Issue 7, 2009, Pages 373-375

  Kaliebe, Jeffrey W ^a   Murdock, David K ^a,b  

^a CaRE Foundation Inc   (United States)

^b Cardiovascular Associates of Northern Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; METOPROLOL; MULTIVITAMIN; OMEPRAZOLE; RANOLAZINE; UBIQUINONE; ACETANILIDE DERIVATIVE; ENZYME INHIBITOR; PIPERAZINE DERIVATIVE;

AGED; ARTICLE; CASE REPORT; DIZZINESS; DYSPEPSIA; FEMALE; HEART CATHETERIZATION; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; NON SUSTAINED VENTRICULAR TACHYCARDIA; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; THORAX PAIN; ELECTROCARDIOGRAPHY; PATHOPHYSIOLOGY;

ACETANILIDES; AGED; ELECTROCARDIOGRAPHY, AMBULATORY; ENZYME INHIBITORS; FEMALE; HUMANS; PIPERAZINES; TACHYCARDIA, VENTRICULAR;

EID: 73349112604     PISSN: 10981861     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Mitchell LB. Role of drug therapy for sustained ventricular tachyarrhythmias. Cardiol Clin. 2008;26(3):405-418.
2. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754-763.
3. Ebinger MW, Krishnan S, Schuger CD. Mechanisms of ventricular arrhythmias in heart failure. Curr Heart Fail Rep. 2005;2:111-117.
4. Janse MJ. Electrophysiological changes in heart failure and their relationship to arrhythmogenesis. Cardiovasc Res. 2004;61:208-217.
5. Pogwizd SM, Bers DM. Calcium cycling in heart failure: the arrhythmia connection. J Cardiovasc Electrophysiol. 2002;13:88-91.
6. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrythmogenesis and contractile dysfunction in heart failure: roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res. 2001;88:1159-1167.
7. Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur Heart J. 2006;Suppl A1,A10-A13.
8. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late Ina in guinea pig ventricular myocytes. J Cardiovasc Pharmacol. 2004;44:192-199.
9. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with anti-arrhythmic properties. Circulation. 2004;110:904-910.
10. Undrovinas AI, Belardelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes in dogs with heart failure by inhibiting late sodium current. J Cardiovasc Electrophysiol. 2006;17(Suppl 1):S169-S177.
11. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45:469-491.
12. Murdock DK, Kaliebe J, Overton N. Ranolozine-induced suppression of ventricular tachycardia in a patient with nonischemic cardiomyopathy: a case report. Pacing Clin Electrophysiol. 2008;31(6):765-768.
13. Scirica BM, Morrow DA, Hod H, et al. Effect of ranolazine, an anti-anginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-1652.